United Therapeutics Corp has a consensus price target of $271.73, established from looking at the 39 latest analyst ratings. The last 3 analyst ratings were released from Wells Fargo, Wedbush, and HC Wainwright & Co. on March 7, 2024, February 22, 2024, and February 22, 2024. With an average price target of $311 between Wells Fargo, Wedbush, and HC Wainwright & Co., there's an implied 31.22% upside for United Therapeutics Corp from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/07/2024 | UTHR | Buy Now | United Therapeutics | $237.00 | 37.13% | Wells Fargo | Tiago Fauth | $309 → $325 | Maintains | Overweight | Get Alert |
02/22/2024 | UTHR | Buy Now | United Therapeutics | $237.00 | 29.96% | Wedbush | Liana Moussatos | → $308 | Reiterates | Outperform → Outperform | Get Alert |
02/22/2024 | UTHR | Buy Now | United Therapeutics | $237.00 | 26.58% | HC Wainwright & Co. | Andrew Fein | → $300 | Reiterates | Buy → Buy | Get Alert |
02/12/2024 | UTHR | Buy Now | United Therapeutics | $237.00 | -9.28% | Goldman Sachs | Chris Shibutani | $213 → $215 | Upgrade | Sell → Neutral | Get Alert |
02/05/2024 | UTHR | Buy Now | United Therapeutics | $237.00 | 39.24% | Leerink Partners | Roanna Ruiz | → $330 | Initiates | → Outperform | Get Alert |
11/02/2023 | UTHR | Buy Now | United Therapeutics | $237.00 | 24.05% | JP Morgan | Jessica Fung | $290 → $294 | Maintains | Overweight | Get Alert |
11/02/2023 | UTHR | Buy Now | United Therapeutics | $237.00 | 32.49% | Morgan Stanley | Terence Flynn | $318 → $314 | Maintains | Overweight | Get Alert |
11/02/2023 | UTHR | Buy Now | United Therapeutics | $237.00 | 29.96% | Wedbush | Liana Moussatos | $307 → $308 | Maintains | Outperform | Get Alert |
08/03/2023 | UTHR | Buy Now | United Therapeutics | $237.00 | 34.18% | Morgan Stanley | Terence Flynn | $316 → $318 | Maintains | Overweight | Get Alert |
08/03/2023 | UTHR | Buy Now | United Therapeutics | $237.00 | 13.08% | Ladenburg Thalmann | Matthew Kaplan | $256 → $268 | Maintains | Buy | Get Alert |
08/03/2023 | UTHR | Buy Now | United Therapeutics | $237.00 | 29.54% | Wedbush | Liana Moussatos | $305 → $307 | Maintains | Outperform | Get Alert |
08/03/2023 | UTHR | Buy Now | United Therapeutics | $237.00 | 26.58% | HC Wainwright & Co. | Andrew Fein | → $300 | Reiterates | Buy → Buy | Get Alert |
05/04/2023 | UTHR | Buy Now | United Therapeutics | $237.00 | 8.02% | Ladenburg Thalmann | Matthew Kaplan | $285 → $256 | Maintains | Buy | Get Alert |
04/21/2023 | UTHR | Buy Now | United Therapeutics | $237.00 | 18.14% | Argus Research | Jasper Hellweg | $300 → $280 | Maintains | Buy | Get Alert |
04/10/2023 | UTHR | Buy Now | United Therapeutics | $237.00 | 30.8% | UBS | Ashwani Verma | $330 → $310 | Maintains | Buy | Get Alert |
04/10/2023 | UTHR | Buy Now | United Therapeutics | $237.00 | 33.33% | Morgan Stanley | Terence Flynn | $320 → $316 | Maintains | Overweight | Get Alert |
02/23/2023 | UTHR | Buy Now | United Therapeutics | $237.00 | 18.14% | JP Morgan | Jessica Fung | $265 → $280 | Maintains | Overweight | Get Alert |
02/23/2023 | UTHR | Buy Now | United Therapeutics | $237.00 | 35.02% | Morgan Stanley | Terence Flynn | $330 → $320 | Maintains | Overweight | Get Alert |
02/23/2023 | UTHR | Buy Now | United Therapeutics | $237.00 | 26.58% | HC Wainwright & Co. | Andrew Fein | → $300 | Reiterates | → Buy | Get Alert |
The latest price target for United Therapeutics (NASDAQ: UTHR) was reported by Wells Fargo on March 7, 2024. The analyst firm set a price target for $325.00 expecting UTHR to rise to within 12 months (a possible 37.13% upside). 13 analyst firms have reported ratings in the last year.
The latest analyst rating for United Therapeutics (NASDAQ: UTHR) was provided by Wells Fargo, and United Therapeutics maintained their overweight rating.
The last upgrade for United Therapeutics Corp happened on February 12, 2024 when Goldman Sachs raised their price target to $215. Goldman Sachs previously had a sell for United Therapeutics Corp.
There is no last downgrade for United Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of United Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for United Therapeutics was filed on March 7, 2024 so you should expect the next rating to be made available sometime around March 7, 2025.
While ratings are subjective and will change, the latest United Therapeutics (UTHR) rating was a maintained with a price target of $309.00 to $325.00. The current price United Therapeutics (UTHR) is trading at is $237.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.